Camlin Fine Sciences Limited has informed the Exchange about press release issued by the Company.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences (CFSL) already acquired a 78.68% stake in French listed company Vinpai in November 2025 at €3.60 per share, and now holds 83.82% of share capital after converting its bonds. CFSL is filing a mandatory cash tender offer (OPAS) for the remaining Vinpai shares at the same price of €3.60, but the draft filing has been pushed back from end-February 2026 to early May 2026, citing Indian forex regulatory constraints and the need to include Vinpai's 2025 annual results (due April 16, 2026). Importantly, CFSL has decided not to do a squeeze-out, so Vinpai will stay listed on Euronext Growth Paris. CFSL is also exploring a European group restructuring to create synergies across its European subsidiaries.
The delay in the tender offer timeline introduces some uncertainty, but the price remains unchanged at €3.60 per share. Deciding not to delist Vinpai preserves CFSL's optionality and access to European capital markets for future growth, while a group restructuring could unlock synergies that benefit shareholders over time.